Weller, Jonathan http://orcid.org/0000-0001-6013-8069
Katzendobler, Sophie
Karschnia, Philipp
Lietke, Stefanie
Egensperger, Rupert
Thon, Niklas
Weller, Michael
Suchorska, Bogdana
Tonn, Joerg-Christian
Funding for this research was provided by:
Universitätsklinik München
Article History
Received: 27 February 2021
Accepted: 22 April 2021
First Online: 1 May 2021
Declarations
:
: Jonathan Weller, Sophie Katzendobler, Philipp Karschnia, Stefanie Lietke, Rupert Egensperger, Niklas Thon and Bogdana Suchorska have no disclosures. Michael Weller has received research grants from Abbvie, Adastra, Apogenix, Merck, Sharp & Dohme (MSD), Merck (EMD), Novocure and Quercis, and honoraria for lectures or advisory board participation or consulting from Abbvie, Adastra, Basilea, Bristol Meyer Squibb (BMS), Celgene, Medac, Merck, Sharp & Dohme (MSD), Merck (EMD), Nerviano Medical Sciences, Novartis, Orbus, Philogen, Roche, Tocagen and yMabs. Joerg-Christian Tonn: Consultant/speaker honoraria from BrainLab and Carthera, and royalties from Springer Publisher Intl.
: Ethics approval was obtained by the Ethics Committee of the Ludwig Maximilian University of Munich (Project Number 20-513).
: The present study was conducted retrospectively.
: Consent to participate in retrospective studies is given prospectively by all patients treated at the Department of Neurosurgery of the Ludwig Maximilian University of Munich through a local, institutional prospective tumor registry.